Patient

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Thursday, August 18, 2022 - 2:21am

SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted.

Key Points: 
  • The supplemental application for additional indications of the companys adalimumab injection (project code: UBP1211, trade name: ), including the treatment of Crohns disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohns disease in children, has been accepted.
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

LFST Shareholder Notification: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against LifeStance Health Group, Inc. (LFST)

Retrieved on: 
Thursday, August 18, 2022 - 1:04am

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of the common stock LifeStance Health Group, Inc.(NASDAQ: LFST) pursuant to or traceable to the Company's June 2021 initial public offering ("IPO"), for violations of the Securities Act of 1933.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of the common stock LifeStance Health Group, Inc.(NASDAQ: LFST) pursuant to or traceable to the Company's June 2021 initial public offering ("IPO"), for violations of the Securities Act of 1933.
  • LifeStance, through its subsidiaries, provides outpatient mental health services in 31 states.
  • If you would like more information about LifeStance Health Group, Inc.'s misconduct, click here .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

MD Office Solutions, LLC, acquires Antigua Medical Services, LLC; a Cardiac Mobile Imaging Company in Arizona

Retrieved on: 
Thursday, August 18, 2022 - 12:20am

HAYWARD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- MD Office Solutions of Arizona, LLC, an Arizona based company, and subsidiary of M.D.O.S.C.A.

Key Points: 
  • HAYWARD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- MD Office Solutions of Arizona, LLC, an Arizona based company, and subsidiary of M.D.O.S.C.A.
  • Antigua is a mobile nuclear medicine services provider based in Arizona with offices in Phoenix and Tucson, and is engaged in diagnostic imaging services similar to MD Office Solutions.
  • Since its founding in 2009, MD Office Solutionshas been a mobile in-office imaging service provider in Northern California.
  • MD Office Solutions utilizes Digirad Healths state of the art equipment with unique mobile, upright imaging, and solid-state technologies.

Prime Healthcare Services Announces Early Tender Results of Its Previously Announced Cash Tender Offer for 7.250% Senior Secured Notes Maturing November 2025 and Extends Total Consideration Pricing to the Expiration Date

Retrieved on: 
Thursday, August 18, 2022 - 12:54am

However, there can be no assurance that the conditions set forth in the Offer to Purchase will be satisfied or waived.

Key Points: 
  • However, there can be no assurance that the conditions set forth in the Offer to Purchase will be satisfied or waived.
  • The Tender Offer is described in the Offer to Purchase, dated August 4, 2022 (as it may be amended or supplemented, the Offer to Purchase).
  • The Tender Offer is subject to the satisfaction or waiver of a number of conditions as set forth in the Offer to Purchase.
  • Fourteen of the Prime Healthcare hospitals are members of the Prime Healthcare Foundation, a 501(c)(3) not-for-profit public charity.

Kiromic Biopharma, Inc. Shareholder Notificaiton: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Kiromic Biopharma, Inc. (KRBP)

Retrieved on: 
Wednesday, August 17, 2022 - 11:37pm

If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .

Key Points: 
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • However, clinical testing did not proceed in the third quarter 2021, nor was it likely given the FDA's imposition of a clinical hold.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC

Retrieved on: 
Wednesday, August 17, 2022 - 11:10pm

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.

Key Points: 
  • WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.

How Might Biomolecular Condensates Revolutionize Drug Discovery? A Perspective from Dewpoint Therapeutics

Retrieved on: 
Wednesday, August 17, 2022 - 11:59pm

BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.

Key Points: 
  • BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.
  • In "Modulating biomolecular condensates: a novel approach to drug discovery," a Dewpoint Therapeutics perspective, the authors discuss the largely untapped opportunities for targeting biomolecular condensates to develop therapeutic agents for various diseases.
  • Condensate-targeted drug discovery was pioneered by Dewpoint Therapeutics as the firstbiotech company to enter the field, founded in 2018.
  • Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery.

Plus Therapeutics Awarded $17.6 Million from State of Texas

Retrieved on: 
Wednesday, August 17, 2022 - 10:46pm

AUSTIN, Texas, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it was awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the continued development of the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM).

Key Points: 
  • The Plus team is honored to receive this significant and esteemed award from CPRIT, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • In the second quarter of 2022, the Company completed enrollment of Cohort 1 in the ReSPECT-LM Phase 1/2a dose escalation trial ( NCT05034497 ).
  • To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.
  • Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.

Premier Autism Therapy Provider Reports on Landmark Clinical Study

Retrieved on: 
Wednesday, August 17, 2022 - 10:45pm

At the inception of this project, ABC sought to understand how the delivery of therapy would best benefit their patients.

Key Points: 
  • At the inception of this project, ABC sought to understand how the delivery of therapy would best benefit their patients.
  • The earlier in a childs life that we can diagnose autism and provide the requisite services, the higher the efficacy of the therapy, said Dr. Claire Schutte, Senior Director of Evaluation and Research at ABC.
  • In a second longitudinal study, school placement following the completion of intervention was evaluated.
  • Founded in 2017, Action Behavior Centers (ABC) is a leading applied behavior therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum.

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

Retrieved on: 
Wednesday, August 17, 2022 - 10:00pm

Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

Key Points: 
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.
  • A recording of the call will be available following the event at the Company's website.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks of Medicure International Inc.